Industry Reports

Oxford BioDynamics is participating in a collaboration to identify the biological factors that trigger disease relapses, known as flares, in Rheumatoid Arthritis (RA), entitled the…
Read More...

Threshold Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for cancer, and Molecular Templates, Inc., a privately held biopharmaceutical…
Read More...

Acura Pharmaceuticals, Inc. and MainPointe Pharmaceuticals, LLC announced that they have entered into a License Agreement (the "Agreement") to have MainPointe exclusively market NEXAFED…
Read More...

Trovagene, Inc., a precision medicine biotechnology company, and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, today announced that they have signed a…
Read More...

Mylan N.V., announced the U.S. launch of Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version of Pfizer's Pristiq® Tablets. Mylan received final approval from…
Read More...

BioreclamationIVT has acquired TransCell Science, a privately held contract research organization (CRO) specializing in the use of primary cells for phenotypic screening assays.  With…
Read More...

Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it completed the sale to Ferring International…
Read More...

BeiGene, Ltd. and Guangzhou Development District (GDD) announced that BeiGene (Hong Kong) Co., Ltd. (BeiGene HK), a wholly owned subsidiary of BeiGene, Ltd. and GDD and its affiliate…
Read More...

Vernalis plc and Servier are pleased to announce that they reinforce their partnership by entering into a new two-year oncology drug discovery collaboration on an undisclosed target.…
Read More...

Sartorius, a leading partner to the biopharmaceutical industry and laboratories, today signed an agreement to acquire U.S. based Essen BioScience Inc., a pioneer and leader in the field…
Read More...

Otsuka Pharmaceutical Co., Ltd. (OPC) today announces an agreement with Neurovance, Inc. (Neurovance) under which OPC has agreed to acquire Neurovance, a privately held, venture-funded,…
Read More...

Glenmark Pharmaceuticals Inc., USA, and Evestra, Inc. have completed a strategic development, license and commercialization agreement to develop and market a generic version of Merck's…
Read More...

Eli Lilly and Company announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. The tender offer for all outstanding shares of common stock of CoLucid, at…
Read More...

Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious infectious diseases, and…
Read More...

Perrigo Company plc, a leading global provider of Quality Affordable Healthcare Products announced it has signed a definitive agreement to divest its rights to the royalty stream from…
Read More...

Ligand Pharmaceuticals announces the completion of enrollment in the Company’s Phase 2 clinical trial with its novel, small-molecule glucagon receptor antagonist LGD-6972 for the…
Read More...

Intellipharmaceutics International, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral…
Read More...

Sanofi and Lonza announced that they have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in…
Read More...

ANI Pharmaceuticals, Inc. announced that it has acquired Inderal XL from Cranford Pharmaceuticals, LLC and InnoPran XL  from Holmdel Pharmaceuticals LP. The acquired assets include the…
Read More...

Portola Pharmaceuticals, Inc.® (PTLA) announced that it has signed a $150 million royalty agreement with HealthCare Royalty Partners (HCR). Under the terms of the agreement, Portola…
Read More...